Oliver Sara E, Hoots Brooke E, Paz-Bailey Gabriela, Markowitz Lauri E, Meites Elissa
*Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, GA; †Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA; and ‡Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA.
J Acquir Immune Defic Syndr. 2017 Jul 1;75 Suppl 3(Suppl 3):S370-S374. doi: 10.1097/QAI.0000000000001413.
Human papillomavirus (HPV) can cause oropharyngeal and anogenital cancers among men who have sex with men (MSM). In 2011, the Advisory Committee on Immunization Practices (ACIP) extended HPV vaccine recommendations to males through age 21 and MSM through age 26. Because of this distinction, vaccination for some MSM might rely on sexual behavior disclosure to health care providers. Receipt of ≥1 HPV vaccination among MSM aged 18-26 in National HIV Behavioral Surveillance (NHBS) was 4.9% in 2011. We evaluated HPV vaccine coverage and associated factors among MSM in 2014.
Twenty US metropolitan statistical areas in 2014.
Coverage was calculated as percentage of MSM self-reporting ≥1 HPV vaccination. Adjusted prevalence ratios were calculated from Poisson regression models to estimate associations of demographic and behavioral characteristics with HPV vaccination.
Among 2892 MSM aged 18-26 years, HPV vaccine coverage was 17.2%. Overall, 2326 (80.4%) reported a health care visit within 12 months, and 2095 (72.4%) disclosed MSM attraction or behavior to a health care provider. Factors associated with vaccination included self-reported HIV infection; having a health care visit within 12 months, health insurance, or a usual place of care; and disclosing MSM attraction or behavior to a health care provider.
Since the 2011 recommendation for vaccination of males, HPV vaccine coverage among MSM increased, but remains low. Most MSM reported a recent health care visit and disclosed sexual behavior, indicating opportunities for vaccination. Potential strategies for increasing MSM coverage include improving access to recommended care, and offering education for providers and patients.
人乳头瘤病毒（HPV）可导致男男性行为者（MSM）发生口咽癌和肛门生殖器癌。2011年，免疫实践咨询委员会（ACIP）将HPV疫苗接种建议扩展至21岁及以下男性以及26岁及以下男男性行为者。由于这一区别，部分男男性行为者的疫苗接种可能依赖于向医疗服务提供者披露性行为。2011年，在全国艾滋病病毒行为监测（NHBS）中，18至26岁的男男性行为者中接种过≥1剂HPV疫苗的比例为4.9%。我们评估了2014年男男性行为者中HPV疫苗接种率及相关因素。
2014年美国20个大都市统计区。
接种率按自我报告接种过≥1剂HPV疫苗的男男性行为者的百分比计算。通过泊松回归模型计算调整后的患病率比值，以估计人口统计学和行为特征与HPV疫苗接种之间的关联。
在2892名18至26岁的男男性行为者中，HPV疫苗接种率为17.2%。总体而言，2326人（80.4%）报告在12个月内进行过医疗就诊，2095人（72.4%）向医疗服务提供者披露过男男性行为倾向或行为。与疫苗接种相关的因素包括自我报告感染艾滋病病毒；在12个月内进行过医疗就诊、拥有医疗保险或有固定的医疗场所；以及向医疗服务提供者披露男男性行为倾向或行为。
自2011年对男性接种疫苗的建议发布以来，男男性行为者中的HPV疫苗接种率有所上升，但仍然较低。大多数男男性行为者报告近期进行过医疗就诊并披露了性行为，这表明存在接种疫苗的机会。提高男男性行为者接种率的潜在策略包括改善获得推荐医疗服务的机会，以及为医疗服务提供者和患者提供教育。
